Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Team

Latest From Scrip Team

Pipeline Watch: 8 Approvals and 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Executives On The Move: Three New CFOs And One New CEO Among This Week's Changes

Recent moves in the industry include C-suite shuffles at MorphoSys, Centessa Pharmaceuticals and Skyhawk Therapeutics, plus bluebird bio acquires a new chief financial officer.

Executive Changes Leadership

Pipeline Watch: Respiratory Syncytial Virus Vaccine approved in the US As ASCO Dominates Clinical Trial Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry. 

BIO Real-World Evidence

Executives On The Move: Assertio Holdings Acquires Chief Executive Officer from Glenmark Pharmaceuticals

Recent moves in the industry include changes at the top for Inhibrx and Monte Rosa Therapeutics, plus Imunon, Avrobio and Kronos Bio acquire chief financial officers from Cyteir Therapeutics, Oyster Point Pharma and Senti Biosciences, respectively.

Leadership Executive Changes

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence. 

BIO Deals
See All
UsernamePublicRestriction

Register